rs1542705–67,992,843-1,050,239 represents a novel informative haplotype at the SMPD1 locus in the Iranian population

The presence of single nucleotide variations in the coding region of micro-RNA (miRNA)- encoding genes plays a significant role in the expression and function of these molecules in oncogenesis and cancer. The association of rs2682818 in miR-618 with increased risk of breast cancer was investigated in the Iranian population. rs2682818/miR-618 was genotyped using amplification-refractory mutation system PCR (ARMS-PCR) in 200 healthy individuals and patients with breast cancer. The data revealed the presence of Hardy-Weinberg equilibrium (HWE) for this marker. The frequency of alleles C and A was 70% and 30%, respectively, in healthy individuals; the frequency of alleles C and A was 44% and 56%, respectively, in patients with breast cancer. Analysis of odd ratios showed that the rs2682818/miR-618 polymorphism is associated with increased probability of breast cancer and is statistically significant (OR=2.97, P=0.0003). The data suggest that rs2682818/miR-618 could be considered a novel marker of increased risk of breast cancer.

show abstract

“…SNPs are the most common variation in the human genome [20,21]. Polymorphisms in miRNAs are in both mature miRNA and pre-miRNA sequences [22,23].…”

Section: Introductionmentioning

confidence: 99%

rs2682818/MiR-618 is a novel marker associated with increased risk of breast cancer in the Iranian population

Najafian-Najafabady

Ebrahimi

Vallian

2021

ARCH BIOL SCI BELGRA

Self Cite

View full text Add to dashboard Cite

show abstract

“…The dysregulation of lncRNAs has been reported in numerous types of cancers, including PCa, while some lncRNAs have been shown to be PCa specific, including PCGEM1 [10], PRNCR1 [11], PCAT1 [12] and SChLAP1 [13]. Many lncRNAs show tissue-and cell type-specific expression patterns and therefore have the potential to be used as diagnostic biomarkers for cancer [14,15].…”

Section: Introductionmentioning

confidence: 99%

Two long non-coding RNAs, CAT179 and CAT 1796, differentiate between benign prostate hyperplasia and prostate cancer

Ebrahimi

Amirmahani

Akbari

et al. 2021

Arch biol sci (Beogr)

Self Cite

View full text Add to dashboard Cite

Several long non-coding RNAs (lncRNAs) have recently emerged as potential biomarkers in cancer biology. In the present study, we examined the expression of four lncRNAs (CAT179, CAT1796, PRCAT47, and CAT1066) to evaluate their ability to discriminate prostate tumors from benign prostate hyperplasia (BPH). Expression of these four lncRNAs was examined in 20 prostate cancer and 20 benign prostate hyperplasia (BPH) samples, as well as in urine samples (11 BPH, and 11 cancer). Total RNA was extracted for cDNA syntheses. The expression of the candidate lncRNAs was evaluated by quantitative real-time PCR (qRT-PCR). The lncRNAs CAT1796 and CAT179 were both upregulated in prostate cancer compared to BPH clinical samples (P<0.05). ROC curve analysis showed that CAT1796 had high sensitivity and specificity for diagnosis of prostate cancer (AUC=0.8151[95%CI 0.65-0.97]), suggesting that CAT1796 lncRNA could be a prostate cancer biomarker.

show abstract

rs1542705–67,992,843-1,050,239 represents a novel informative haplotype at the SMPD1 locus in the Iranian population

Cited by 2 publications

References 32 publications

rs2682818/MiR-618 is a novel marker associated with increased risk of breast cancer in the Iranian population

rs2682818/MiR-618 is a novel marker associated with increased risk of breast cancer in the Iranian population

Two long non-coding RNAs, CAT179 and CAT 1796, differentiate between benign prostate hyperplasia and prostate cancer

Contact Info

Product

Resources

About